My Portfolio
+
LINK YOUR PORTFOLIO

Geron Corp GERN:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 7:30 PM EDT
1.16UNCH (UNCH)
Volume
113,371
Close
1.16quote price arrow down-0.01 (-0.85%)
Volume
9,940,563
52 week range
1.04 - 2.01
Loading...
  • Open1.18
  • Day High1.19
  • Day Low1.14
  • Prev Close1.17
  • 52 Week High2.01
  • 52 Week High Date02/19/26
  • 52 Week Low1.04
  • 52 Week Low Date11/07/25

Latest On Geron Corp

 

Key Stats

  • Market Cap744.164M
  • Shares Out641.52M
  • 10 Day Average Volume9.64M
  • Dividend-
  • Dividend Yield-
  • Beta0.60

Latest On Geron Corp

 

KEY STATS

  • Open1.18
  • Day High1.19
  • Day Low1.14
  • Prev Close1.17
  • 52 Week High2.01
  • 52 Week High Date02/19/26
  • 52 Week Low1.04
  • 52 Week Low Date11/07/25
  • Market Cap744.164M
  • Shares Out641.52M
  • 10 Day Average Volume9.64M
  • Dividend-
  • Dividend Yield-
  • Beta0.60

RATIOS/PROFITABILITY

  • EPS (TTM)-0.10
  • P/E (TTM)-11.50
  • Fwd P/E (NTM)580.00
  • EBITDA (TTM)-34.608M
  • ROE (TTM)-27.07%
  • Revenue (TTM)196.115M
  • Gross Margin (TTM)97.33%
  • Net Margin (TTM)-34.32%
  • Debt To Equity (MRQ)108.95%

EVENTS

  • Earnings Date08/04/2026(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Profile

MORE
Geron Corporation is a commercial-stage biopharmaceutical company. The Company develops first-in-class telomerase inhibitor, RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS), with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). RYTELO...
Elizabeth O'Farrell
Lead Independent Chairman of the Board
Harout Semerjian
President, Chief Executive Officer, Director
Michelle Robertson
Chief Financial Officer, Executive Vice President - Finance, Treasurer
Ahmed Elnawawi
Executive Vice President, Chief Commercial Officer
Joseph Eid M.D.
Executive Vice President - Research and Development
Address
919 East Hillsdale Boulevard, Suite 250
Foster City, CA
94404
United States